

## Women’s and Reproductive Health Guidelines Update Committee Meeting 40

**Date:** 7 September 2023

**Location** Virtual via Microsoft Teams

**Minutes:** Confirmed

<b>Committee members present:</b>	
Sarah Fishburn (Chair)	Present for notes 1 – 6
Maggie Blott (Topic Advisor)	Present for notes 2 – 6
Maria Clark	Present for notes 1 – 6
Lucy O’Malley	Present for notes 1 – 6
Sarah Griffiths	Present for notes 1 – 6
Aung Soe	Present for notes 1 – 6
Ashifa Trivedi	Present for notes 1 – 6
Alena Chong	Present for notes 1 – 6
Bryony Kendall	Present for notes 1 – 6

<b>In attendance:</b>		
Hilary Eadon	NICE Guideline Lead	Present for notes 1 – 6
Hayley Shaw	NICE Project Manager	Present for notes 1 – 6
Sharangini Rajesh	NICE Senior Technical Analyst	Present for notes 1 – 6
Stephanie Arnold	NICE Information Scientist	Present for notes 1 – 6
Rebecca Blackburn	NICE Technical Analyst	Present for notes 1 – 6
Paul Jacklin	NICE Senior Health Economist	Present for notes 2 – 6
Ayisha Ashmore	NICE Clinical Fellow	Present for notes 1 – 6
Gareth Haman	NICE Senior Medical Editor	Present for notes 1 – 6
Suzie Panek	NICE Finance Analyst	Present for notes 1 – 6
Clifford Middleton	NICE Guideline Commissioning Manager	Present for notes 4 – 6
Maria Majeed	Technical Analyst (Guideline Surveillance)	Present for notes 4 – 5
Kay Nolan	Associate Director (Guideline Surveillance)	Present for notes 4 – 5

<b>Apologies:</b>	
Chimwemwe Kalumbi	Committee member
Cornelia Wiesender	Committee member
Sophie McAllister	Committee member
Frances Rivers	Committee member
Sophie House	Committee member
Tim Watts	Committee member
Qudsia Malik	Senior Technical Analyst
Agnesa Mehmeti	Technical Analyst
Aye Paing	Technical Analyst
Benjamin Gregory	Business Analyst

**1. Welcome and objectives for the meeting.**

The Chair welcomed the committee to the 40<sup>th</sup> Women’s and Reproductive Health guideline committee meeting.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives for the meeting, which included discussing the twin and triplet protocol and a surveillance discussion.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion was twin and triplet pregnancy.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. One new interest was declared:

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Ashifa Trivedi	Committee Member	Direct, financial	1 year secondment as the Chief Pharmaceutical Officer’s Clinical Fellow.  (Working on the medicines optimisation and pharmacy	September 23	September 23	Ongoing (until 31 <sup>st</sup> August 2024)	Non-specific Declare and participate.  Rationale: Salaried employment in DHSC. Secondment to a role

			procurement team for the London Procurement Partnership (LPP) which is employed by the 5 ICSs across London to help with procurement, consensus statements and an interface prescribing policy).				working on projects for London ICSSv and not a national role is not a conflict with the development of the guideline.
<b>3. Minutes of last meeting</b>							
The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed that no changes were required.							
<b>4. Presentations</b>							
The Chair introduced Rebecca Blackburn, Technical Analyst, and Sharangini Rajesh, Senior Technical Analyst, who presented the T&T1 protocol: What is the clinical and cost-effectiveness of progesterone in preventing spontaneous preterm birth in twin and triplet pregnancy?							
The Chair introduced Maria Majeed, Surveillance Analyst who led on a surveillance discussion regarding wound care after a caesarean birth with the committee.							
<b>5. Questions and discussions</b>							
The committee discussed the protocol for T&T1 and the reasons for the change to a full systematic review. The committee agreed on the protocol for the full systematic review.							
The committee had a discussion with the surveillance team.							
<b>6. Any other business</b>							
The meeting was closed at 12:10.							

**Date of next meeting:**

- **Wednesday 27<sup>th</sup> September (all day)**

**Location of next meeting:** Virtual via Microsoft Teams